Articles On Orthocell (ASX:OCC)

Orthocell Ltd (ASX: OCC) is an Australian medical technology company focused on developing and commercialising innovative regenerative medicine treatments.  Over the last 12 months its share price has skyrocketed, up more than 260% in t...

The ASX has pared losses and has been down 1.25% at 7,835 points this morning. Information Technology has been the biggest loser, followed by Energy and Real Estate. Staples has been the only sector to buck the trend and gain ground....

Donald Trump exempts “pharmaceuticals” from his tariff blitz ASX device makers mull their US manufacturing plans as Ansell shares plunge Race and Imugene progress their early-stage oncology trials   Liberation Day has spared the pharmaceu...

S&P/ASX 200 Index (ASX: XJO) gold stock Ramelius Resources Ltd (ASX: RMS) is charging higher today. Ramelius shares closed yesterday trading for $2.30. In morning trade on Thursday, shares are swapping hands for $2.41 apiece, up 4.8%....

Healthcare and medical manufacturing in Australia is gaining momentum supported by initiatives from federal and state governments CSL, IDT Australia, Optiscan and Trajan Group among healthcare companies with manufacturing facilities in Mel...

The S&P/ASX 200 Index (ASX: XJO) had a nervous yet positive end to the trading week this Friday. After yesterday's drop, investors didn't seem to know what to do for most of the day, but the ASX...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

As most investors would be aware, it's been a rough few months for the stock market. Since the start of November, the S&P/ASX 200 Index (ASX: XJO) is nursing a 1.5% loss despite the 3.2% rally it has enjoyed over the past two weeks. Wit...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.35% to 7,997.6 points. Four ASX shares that are rising more than most today are listed below....

Stockhead joins with IR Department and Morgans for HealthInvest 2025 in Sydney on April 2 Event to highlight some of ASX’s leading up-and-coming health and life sciences companies EMVision, Microba Life Sciences, Orthocell, Lumos Diagnosti...

The team at Bell Potter has been busy running the rule over the healthcare sector and has picked out a number of stocks that it believes are attractive options right now. Let's see what the broker is recommending investors buy now: Clinuve...

Orthocell (ASX:OCC) is set to kick off sales in Germany, Austria and Switzerland for its dental guided bone and tissue regeneration product Striate+, gaining exposure to a market valued over $1 billion.  Watch the video to hear more.   Thi...

Orthocell (ASX: OCC) has achieved the first sales of its dental guided bone and tissue regeneration product Striate+ into new markets in Germany, Austria and Switzerland through exclusive global distribution partner BioHorizons Implant Syst...

In afternoon trade S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.8% to 8,004.2 points. Four ASX shares that are rising more than most today are listed below. Here...

It’s up and go time for LTR in the US market All the budget healthcare news – and it’s a short item Prescient launches phase 2a study for a rare blood cancer   The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR P...

It has been a rough stretch for many ASX lithium stocks recently, but one name is bucking the trend in a big way today. Vulcan Energy Resources Ltd (ASX: VUL) shares are surging higher in Tuesday thanks to some big news. At the time of writ...

Despite the current political upheaval, the US health sector remains the first port of call for most biotechs FDA approvals have sparked one-day share surges of as much as 500% Several ASX companies await do-or-die FDA approvals Despite r...

It was a rather unremarkable day for the S&P/ASX 200 Index (ASX: JXO) and most ASX 200 shares this Tuesday. By the time trading wrapped up, the ASX 200 had advanced by a nervous 0.08%, leaving the index at 7,860.4 points. But it was a v...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Tylah Tully gives the skinny on Orthocell (ASX:OCC) latest advancement for Striate+, landing market entry into Singapore through its dist...

Highlights: ASX200 registered a marginal gain, reflecting mixed sector performance. Utilities led gains, while Discretionary and Financial sectors saw declines. Key corporate updates influenced stock movements across multipl...

The ASX200 pared early gains to close up by a sliver of less than a tenth of a percent at 7860 points. Utilities was the best performing sector, up 1.7%, followed by Real Estate, up 0.7%, and Energy, up 0.6%. Discretionay was the wors...

The S&P/ASX 200 Index (ASX: XJO)'s recovery continued this Tuesday, with the index building on the gains we saw yesterday to push slightly higher. By the time the markets closed, the ASX 200 had...

The right portfolio of ASX passive income shares can offer a big boost to your retirement lifestyle. And the sooner you start building up that income portfolio, the bigger that boost is likely to be. If you're 30 and aim to retire at 67, th...

Orthocell (ASX: OCC) has received regulatory approval from Singapore’s Health Sciences Authority to commence regional sales of its dental membrane product Striate+ for use in guided bone and tissue regeneration applications. The company sai...

The S&P/ASX 200 Index (ASX: XJO) is on form again and pushing higher on Tuesday. In afternoon trade, the benchmark index is up 0.2% to 7,870.2 points. Four ASX shares that are rising more than most today are listed below. Here's why th...

S&P/ASX 200 Index (ASX: XJO) gold stock West African Resources Ltd (ASX: WAF) is shining bright today. Again. West African Resource shares closed yesterday trading for $2.24. In early afternoon trade on Tuesday, shares are changing han...

Telix Pharmaceuticals’ Brazilian win marks its first foray into the South American market Orthocell gains approval to sell its dental guided bone regeneration product in Singapore Sigma Healthcare: great prospects, a pity about the valuati...

A strong performance from a range of ASX shares today sees the All Ordinaries Index (ASX: XAO) up 0.34% at the time of writing. With the All Ords now in the green for the third consecutive day running, the Aussie stock market is edging furt...

ASX 200 healthcare share Clarity Pharmaceuticals Ltd (ASX: CU6) is the strongest gainer of the S&P/ASX 200 Index (ASX: XJO) on Tuesday. Clarity Pharmaceuticals shares rocketed 13.8% to an intraday high of $2.89 in early trading toda...

Gold has been one of the most interesting corners of the investment markets to watch recently. Whether it be raw bullion prices or the performance of gold exchange-traded funds (ETFs) on the ASX, these investments have been on a tear of lat...

Orthocell Ltd (ASX: OCC) shares are catching the eye again on Tuesday. In morning trade, the ASX healthcare stock is up 11% to $1.53. This means that the regenerative medicine company's shares are now up 290% since this time last year. To p...

New Hope Corporation Ltd (ASX: NHC) shares are on the move on Tuesday morning. At the time of writing, the coal miner's shares are up 8% to $3.99. This follows the release of its half year results before the market open. New Hope shares jum...

The iShares Core S&P/ASX 200 ETF (ASX: IOZ) has gone through a dip in the last few weeks as the global share market has suffered from worries about a trade war between the US and various countries. As the chart above shows, the IO...

Orthocell Ltd (ASX: OCC) share price is catching the eye of investors on Monday. In late afternoon trade, the regenerative medicine company's shares are up over 10% to $1.37. This means that Orthocell shares are now up approximately 250% si...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Highlights Several ASX-listed biotech companies are nearing FDA approval, signifying potential entry into the crucial U.S. market. The FDA has improved its communication with applicants, fostering a more predictable approval process....

Having lodged their paperwork, companies including EBR Systems, Artyra and Orthocell await crucial FDA approval The agency has improved its communications with applicants, which avoids nasty surprises Applicants are doing the commercial gr...

Highlights: Fisher & Paykel Healthcare (ASX:FPH) faces new tariffs but is adapting with strategic measures. Orthocell (ASX:OCC) is progressing with regulatory approvals in multiple markets. Life-sciences...

Telix Pharmaceuticals (ASX:TLX) has joined a somewhat quiet cohort of ASX biotech companies having a pretty good run lately, in some cases outperforming just about everything else. (Just think: Mesoblast, Orthocell, Clarity Pharmaceutica...

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the first hour of trade to $4.23 in what is...

  Early sales transaction has been achieved for Remplir across major jurisdictions A global expansion is underway to increase revenue opportunities The company is planning to broaden its commercial footprint in existing and new markets...

The ASX200 closed up 0.33% at 8,429 points. This was a seven-week closing high, achieved amidst positive sentiment as investors react to Donald Trump’s “Stargate” plan for AI investment, and an initially better than expected trade outcom...

ASX climbs as tech stocks lead the charge Trump’s $500b AI plan boosts tech stocks Tariff talk sparks gains for uranium stocks, losses for iron ore miners   Wednesday saw another climb for the Aussie stock market as the S&P/ASX 200 in...

WA biotech Orthocell will accelerate plans to enter five new markets this year, buoyed by the early sales traction recorded in Australia, New Zealand and Singapore for its flagship nerve repair product.

Pacific Edge flags a legal challenge to a ruling that excludes its bladder cancer test from US public reimbursement ‘Pfizer Riser’ challenger LTR Pharma readies for Australian approval with a national distribution deal Nerve-repair house O...

Highlights  ASX poised to climb as US markets rally overnight.  US tech and healthcare stocks shine, bolstering sentiment.  Oil prices slide as energy policies raise output concerns.  The Australian stock market is set for another...

ASX edges up, Trump’s return on the radar Bitcoin dips after hitting $106k, Star Entertainment Group tanks Banks push ASX higher, Karoon Energy struggles   The ASX saw a small but steady rise on Monday, up 0.45% as traders nervously eyed...

ASX up again after surprise inflation spike Miners led gains as financials rode rate bet Energy Transition Minerals soared on Trump talk   The ASX kept its momentum rolling, up 0.77% on Wednesday as an inflation report surprise gave the R...

Wound care company Avita Medical slumps ~19% on downgrade of its earnings guidance Infection-control medtech Next Science hit with legal action by a former employee Biotech Orthocell achieves third consecutive quarter of record revenue  ...

Orthocell achieves third consecutive quarter of record revenue, reporting $2.21 million in Q2 FY25 Growth attributed to increase in sales of its Striate+ and Remplir products Regulatory approval of Remplir in US expected in March/April 202...